Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences C (JFNCX)

60.54 +0.10 (+0.17%)
At close: April 26 at 8:00 PM EDT

Performance Overview

Morningstar Return Rating --
YTD Return 2.54%
5y Average Return 9.98%
Number of Years Up 12
Number of Years Down 2
Best 1Y Total Return (Apr 26, 2024) 54.39%
Worst 1Y Total Return (Apr 26, 2024) --
Best 3Y Total Return 54.39%
Worst 3Y Total Return 2.84%

Trailing Returns (%) Vs. Benchmarks

Monthly Total Returns
JFNCX
Category
YTD
8.32%
7.95%
1-Month
1.65%
4.81%
3-Month
8.32%
7.18%
1-Year
17.07%
30.16%
3-Year
6.64%
16.10%
5-Year
10.58%
15.71%
10-Year
10.63%
15.27%
Last Bull Market
24.49%
23.06%
Last Bear Market
-8.45%
-13.88%

Annual Total Return (%) History

Year
JFNCX
Category
2024
--
--
2023
6.49%
--
2022
-3.54%
--
2021
5.88%
--
2020
24.47%
27.63%
2019
28.10%
26.23%
2018
3.34%
-0.40%
2017
21.47%
24.31%

2016
-13.18%
-10.60%
2015
7.33%
8.05%
2014
33.65%
27.25%
2013
54.39%
48.17%
2012
23.54%
21.55%
2011
6.36%
7.66%
2010
7.24%
8.38%
2009
--
22.48%

Past Quarterly Returns

YearQ1Q2Q3Q4
2024 8.32% -- -- --
2023 -1.48% 4.41% -4.34% 8.22%
2022 -5.43% -8.45% -2.10% 13.81%
2021 -2.87% 6.84% -1.08% 3.15%
2020 -13.82% 20.76% 5.04% 13.86%
2019 13.60% 1.98% -6.76% 18.59%
2018 3.51% 4.95% 9.85% -13.40%
2017 11.63% 6.95% 4.02% -2.20%
2016 -13.69% 5.45% 4.15% -8.40%
2015 12.94% 4.17% -12.78% 4.60%

2014 6.93% 5.89% 7.04% 10.27%
2013 14.45% 5.65% 16.22% 9.87%
2012 14.90% -0.46% 8.45% -0.39%
2011 6.79% 5.91% -13.74% 9.01%
2010 3.86% -12.18% 12.03% 4.95%
2009 5.60% -- -- --

Rank in Category (By Total Return)

YTD 33
1-Month 57
3-Month 33
1-Year 22
3-Year 24
5-Year 21

Load Adjusted Returns

1-Year 16.07%
3-Year 6.64%
5-Year 10.58%
10-Year 10.63%

Performance & Risk

YTD Return 2.54%
5y Average Return 9.98%
Rank in Category (ytd) 33
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.73
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 5.37B
YTD Return 8.32%
Yield 0.00%
Morningstar Rating
Inception Date Jul 06, 2009

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers